# Treatment of Chronic Hepatitis C With Pegylated Interferon and Ribavirin in Participants With/Without Substitution Therapy (P05255)

> **NCT00725751** · — · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 353 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **BIOLOGICAL:** Pegylated interferon alfa-2b (PegIFN-2b)
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT00725751
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2011-03
- **Final completion:** 2011-03
- **Target enrollment:** 353 (ACTUAL)
- **Last updated:** 2015-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00725751

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00725751, "Treatment of Chronic Hepatitis C With Pegylated Interferon and Ribavirin in Participants With/Without Substitution Therapy (P05255)". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT00725751. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*